Shares in Argenica Therapeutics were down by 13 per cent on Friday morning, despite the biotechnology technology announcing it would raise $12 million in order to complete its second phase trial of its ARG 007 drug in ischaemic stroke patients.
Argenica taps investors for $12m
12/04/2024 - 11:00
Your single user subscription provides more than you think
Extensive & innovative
WA business database
WA business database
The most powerful knowledgebase mapped from 20 years of research and insight into every WA
leader and business.
Never miss a story with
BN daily emails
BN daily emails
Morning and afternoon timely wrap ups of every news item delivered straight to your device.
Directors, businesses
lists and projects
lists and projects
Transaction records, directors wealth, remuneration data and network activity.
Specialised reports
and profile events
and profile events
Get the inside scoop on every news story and connect with WA’s biggest leaders.
Just want the daily emails? Sign up to our free newsletters
